Stockreport

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancerConference call to be [Read more]